Patent: 10,543,283
✉ Email this page to a colleague
Summary for Patent: 10,543,283
Title: | Intranasal administration of guanidinylated aminoglycosides |
Abstract: | This disclosure relates to intranasal administration of conjugates comprising guanidinylated aminoglycosides (\"guanidinoglycosides\") and a polypeptide (e.g., an enzyme, antibody, or polypeptide growth factor). For example, such administration methods are useful for delivering a polypeptide to the brain and/or cerebrospinal fluid. Such methods are useful for treating a lysosomal storage disease through intranasal administration of a conjugate comprising one or more guanidinoglycosides and an enzyme useful for treating a lysosomal storage disease. |
Inventor(s): | Esko; Jeffrey D. (San Diego, CA), Tor; Yitzhak (San Diego, CA), Tong; Wenyong (San Diego, CA) |
Assignee: | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) |
Application Number: | 15/696,690 |
Patent Claims: | see list of patent claims |
Details for Patent 10,543,283
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2033-03-13 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2033-03-13 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2033-03-13 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2033-03-13 |
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | 11/14/2014 | ⤷ Try a Trial | 2033-03-13 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 10/12/2004 | ⤷ Try a Trial | 2033-03-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |